🇺🇸 FDA
Pipeline program

3-V Bioscience-2640

2006432

Phase 2 small_molecule completed

Quick answer

3-V Bioscience-2640 for Metabolic Syndrome is a Phase 2 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Sagimet Biosciences
Indication
Metabolic Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials